"...As of February 12, 2013 the Reporting Persons, in the aggregate, beneficially own 2,992,608 shares of the Common Stock of the Issuer, representing
approximately 7.9% of such class of securities. The beneficial ownership of each Reporting Person is as follows: (i) Fund beneficially owns 1,730,679 shares
of Common Stock representing approximately 4.6% of the class and (ii) Capital, as the investment adviser and sole general partner of the Fund
and investment adviser to an account owned by a separate investment vehicle which holds shares of the Issuer's Common Stock, and Mr. Kolchinsky as the
manager of Capital, each beneficially own 2,992,608 shares of Common Stock of the Issuer representing approximately 7.9% of the class. The percentage of
Common Stock beneficially owned by each Reporting Person is based on a total of 37,704,138 shares of Common Stock of the Issuer outstanding as reported
on Issuer’s Form 10-Q filed with the SEC on November 07, 2012 and the Issuer’s Form 8-K filed with the SEC on February 12, 2013..."
At RA Capital, we take an evidence-based approach to investing globally in innovative healthcare and life sciences companies. We strive to recognize success early and to appreciate the full extent of value creation of which a company is capable.
What a coincidence! RA Capital Management also took a 2.9m position in SGMO (Sangamo Bioscience) at the end of October according to the 13G. At the time, the pps was $5 and change,
and it closed at $9.81 on Jan. 23. Guess which of our favorite posters were very active on the SGMO board? Small world, eh?
Interesting, the fund manager is Dr. Peter Kolchinsky, PhD in Virology from Harvard before moving into money. Looks like they stick with small cap biotech and medical equipment companies and appear to have been very active investors in some companies. Where did this come from?